These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 30446251)

  • 1. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
    Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
    J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of FOXP3
    Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
    Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo maintenance of human regulatory T cells during CD25 blockade.
    Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
    J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25 High CD4+ T cells.
    Van Belle TL; Dooms H; Boonefaes T; Wei XQ; Leclercq G; Grooten J
    PLoS One; 2012; 7(9):e45299. PubMed ID: 23028916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTD-hFOXP3 protein acts as an immune regulator to convert human CD4(+)CD25(-) T cells to regulatory T-like cells.
    Liu X; Xu X; Lin X; Tian Y; Ji B; Xia S; Xu S; Yin Q; Zhang M; Jiao Z; Wang S; Xu H; Shao Q
    J Cell Biochem; 2012 Dec; 113(12):3797-809. PubMed ID: 22806628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
    Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
    J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation.
    Li Z; Lin F; Zhuo C; Deng G; Chen Z; Yin S; Gao Z; Piccioni M; Tsun A; Cai S; Zheng SG; Zhang Y; Li B
    J Biol Chem; 2014 Sep; 289(39):26872-26881. PubMed ID: 25096571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional defects in CD4
    Guo H; Zheng M; Zhang K; Yang F; Zhang X; Han Q; Chen ZN; Zhu P
    Sci Rep; 2016 Nov; 6():37559. PubMed ID: 27901054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
    Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
    Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo.
    Chen Q; Kim YC; Laurence A; Punkosdy GA; Shevach EM
    J Immunol; 2011 Jun; 186(11):6329-37. PubMed ID: 21525380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination
    DeOca KB; Moorman CD; Garcia BL; Mannie MD
    Front Immunol; 2020; 11():541619. PubMed ID: 33072087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation.
    Yang BH; Hagemann S; Mamareli P; Lauer U; Hoffmann U; Beckstette M; Föhse L; Prinz I; Pezoldt J; Suerbaum S; Sparwasser T; Hamann A; Floess S; Huehn J; Lochner M
    Mucosal Immunol; 2016 Mar; 9(2):444-57. PubMed ID: 26307665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
    Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
    Front Immunol; 2022; 13():974188. PubMed ID: 36059465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R.
    Zhao J; Zhao J; Perlman S
    PLoS One; 2012; 7(9):e46241. PubMed ID: 23029447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
    Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
    Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.
    Burchill MA; Yang J; Vogtenhuber C; Blazar BR; Farrar MA
    J Immunol; 2007 Jan; 178(1):280-90. PubMed ID: 17182565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.
    Murer P; Brannetti B; Rondeau JM; Petersen L; Egli N; Popp S; Regnier C; Richter K; Katopodis A; Huber C
    MAbs; 2024; 16(1):2381891. PubMed ID: 39041287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.